We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
 PerkinElmer Joins European Alliance for Newborn Screening in Spinal Muscular Atrophy
News

PerkinElmer Joins European Alliance for Newborn Screening in Spinal Muscular Atrophy

 PerkinElmer Joins European Alliance for Newborn Screening in Spinal Muscular Atrophy
News

PerkinElmer Joins European Alliance for Newborn Screening in Spinal Muscular Atrophy

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of " PerkinElmer Joins European Alliance for Newborn Screening in Spinal Muscular Atrophy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PerkinElmer today announced that the company has joined the European Alliance for Newborn Screening in Spinal Muscular Atrophy, also known as the SMA NBS Alliance.

Founded by SMA Europe, the SMA NBS Alliance has two primary objectives: to decrease the time it takes for a child born with SMA to be diagnosed through newborn screening (NBS), and to assist patient advocacy groups in their efforts to accelerate the identification of such children, given that early diagnosis and treatment leads to better outcomes.

SMA is a rare, progressive, neuromuscular disease that leads to immobility and results in a short life expectancy for many children diagnosed with the condition. NBS offers healthcare providers an opportunity to diagnose and treat children with SMA before motor neuron destruction occurs, giving children affected by this condition the best possible quality of life.

The SMA NBS Alliance demands that by 2025, NBS programs in Europe include a test for SMA for all newborn children. Working toward this goal, Alliance members take part in a variety of activities and are responsible for organizing events in their respective countries to request that health regulators evaluate adding SMA to newborn screening panels.

The founding members of the SMA NBS Alliance include the national SMA patient organizations that are part of SMA Europe, EURORDIS – Rare Diseases Europe, the European Alliance of Neuromuscular Disorders Associations, TREAT-NMD and several global pharmaceutical companies.

The incidence of SMA is approximately 1 in 10,000 live births and it is one of the leading genetic causes of infant death worldwide. Diagnosing SMA quickly is crucial to stopping progression of the disease, which robs infants of valuable motor neurons that allow them to walk, sit and even breathe. Early detection and diagnosis may mean the difference between life and death for an infant with a severe form of SMA.

To learn more about all of PerkinElmer’s newborn screening offerings, visit newbornscreening.perkinelmer.com 

Advertisement